T. Rowe Price Group Inc. (NASDAQ:TROW) is a financial services holding company that focuses on providing global investment management services to individual and institutional investors in T. Rowe Price mutual funds and other investment portfolios. The company's net revenues for 2015 totaled $4.20 billion, which increased from $3.98 billion generated in 2014. Investment advisory revenues derived from the T. Rowe Price mutual funds increased $182.1 million or 7.3% year-on-year to approximately $2.7 billion due to higher average mutual fund assets. The company's 2015 average mutual fund assets increased 7.1% year-on-year to $493.6 billion. Meanwhile, investment advisory revenues earned on other investment portfolios were $1.0 billion, which increased $40.7 million or 4.2% year-on-year. It should be mentioned that T. Rowe Price is a major shareholder of Valeant Pharmaceuticals Intl Inc. (NYSE:VRX), with its mutual funds holding the third-largest stake in the battered company.